S
Steven G. Terra
Researcher at Pfizer
Publications - 60
Citations - 2987
Steven G. Terra is an academic researcher from Pfizer. The author has contributed to research in topics: Placebo & Pharmacokinetics. The author has an hindex of 20, co-authored 54 publications receiving 1695 citations. Previous affiliations of Steven G. Terra include Harvard University.
Papers
More filters
Journal ArticleDOI
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon,Richard Pratley,Samuel Dagogo-Jack,James P. Mancuso,Susan Huyck,Urszula Masiukiewicz,Bernard Charbonnel,Robert Frederich,Silvina Gallo,Francesco Cosentino,Weichung Shih,Ira Gantz,Steven G. Terra,David Z.I. Cherney,Darren K. McGuire +14 more
TL;DR: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events.
Journal ArticleDOI
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K. McGuire,Weichung Shih,Weichung Shih,Francesco Cosentino,Bernard Charbonnel,David Z.I. Cherney,Samuel Dagogo-Jack,Richard E. Pratley,Michelle Greenberg,Shuai Wang,Susan Huyck,Ira Gantz,Steven G. Terra,Urszula Masiukiewicz,Christopher P. Cannon +14 more
TL;DR: This meta-analysis uses data from patients with type 2 diabetes from 6 outcomes trials to investigate the association of sodium-glucose cotransporter 2 inhibitors with cardiovascular- and kidney disease–related outcomes.
Journal ArticleDOI
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
Francesco Cosentino,Christopher P. Cannon,David Z.I. Cherney,Urszula Masiukiewicz,Richard E. Pratley,Samuel Dagogo-Jack,Robert Frederich,Bernard Charbonnel,James P. Mancuso,Weichung Shih,Steven G. Terra,Nilo B. Cater,Ira Gantz,Darren K. McGuire +13 more
TL;DR: In patients with type 2 diabetes mellitus, ertugliflozin reduced the risk for first and total HHF andtotal HHF/CV death, adding further support for the use of sodium-glucose cotransporter 2 inhibitors in primary and secondary prevention of HHF.
Journal ArticleDOI
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
Julio Rosenstock,Juan P. Frias,Dénes Páll,Bernard Charbonnel,Raluca Pascu,Didier Saur,Amanda Darekar,Susan Huyck,Harry Shi,Brett Lauring,Steven G. Terra +10 more
TL;DR: The efficacy and safety of ertugliflozin, an SGLT2 inhibitor, in type 2 diabetes mellitus (T2DM) inadequately controlled with metformin monotherapy with≥1500 mg/d for ≥8 weeks is evaluated.
Journal ArticleDOI
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Richard E. Pratley,Roy Eldor,Annaswamy Raji,Gregory T. Golm,Susan Huyck,Yanping Qiu,Sheila Sunga,Jeremy Johnson,Steven G. Terra,James P. Mancuso,Samuel S. Engel,Brett Lauring +11 more
TL;DR: To evaluate the efficacy and safety of ertugliflozin and sitagliptin co‐administration vs the individual agents in patients with type 2 diabetes who are inadequately controlled with metformin.